67452-97-5 Usage
Description
Vaderm, also known as Alclometasone dipropionate, is a synthetic glucocorticoid steroid with various applications in the medical field. It is characterized by an alpha-chloro substituent at the 7-position and an alpha-methyl substituent at the 16-position. Vaderm is used for its anti-inflammatory, antipruritic, antiallergic, antiproliferative, and vasoconstrictive properties.
Uses
Used in Dermatology:
Vaderm is used as a topical agent for various skin conditions due to its anti-inflammatory, antipruritic, antiallergic, antiproliferative, and vasoconstrictive properties. It helps in reducing inflammation, itching, and allergic reactions, as well as controlling the growth of skin cells and constricting blood vessels.
Used in Pharmaceutical Industry:
As a metabolite of Alclometasone dipropionate (A514580), Vaderm plays a significant role in the development of synthetic glucocorticoid steroids for medical use. It is an essential component in the formulation of various dermatological medications, contributing to their effectiveness in treating skin conditions.
Brand Name:
Aclovate (GlaxoSmithKline) is a brand name under which Vaderm is marketed, making it easily recognizable and accessible to patients and healthcare professionals.
Check Digit Verification of cas no
The CAS Registry Mumber 67452-97-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,7,4,5 and 2 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 67452-97:
(7*6)+(6*7)+(5*4)+(4*5)+(3*2)+(2*9)+(1*7)=155
155 % 10 = 5
So 67452-97-5 is a valid CAS Registry Number.
InChI:InChI=1/C22H29ClO5/c1-11-6-14-18-15(23)8-12-7-13(25)4-5-20(12,2)19(18)16(26)9-21(14,3)22(11,28)17(27)10-24/h4-5,7,11,14-16,18-19,24,26,28H,6,8-10H2,1-3H3/t11-,14+,15-,16+,18-,19+,20+,21+,22+/m1/s1
67452-97-5Relevant articles and documents
Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
-
, (2008/06/13)
Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
7α-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor
-
, (2008/06/13)
Novel 3,20-dioxo-7α-halogeno-1,4-pregnadienes are described and their use as anti-inflammatory agents. Preferred are 7α-bromo- and 7α-chloro- derivatives, particularly 7α-bromo- and 7α-chloro-1,4-pregnadienes-11β,17α,21-triol-3,20-dione 17,21-dihydrocarboncarboxylates, the 16-methyl and 16-methylene derivatives thereof being particularly valuable as topical anti-inflammatory agents.
